trial · primary record
cabotegravir/rilpivirine (600mg/ 900mg)
HIV-1-infection
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2027-02-28 |
| Primary endpoint | HIV-1 RNA <200 copies/mL |
| Registry ID | NCT06507059 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:37.847Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06507059
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.